#NephJC Transcript
Healthcare social media transcript of the #NephJC hashtag.
– ().
See #NephJC Influencers/Analytics.
| Profile | Tweet |
|---|---|
 | Swapnil Hiremath @hswapnil@bsky.social @hswapnil RT @DearbhlaKelly4: |
 | SP @Caring4u2 RT @hswapnil: Swapnil Hiremath #nephjc cofounder, from @OttawaHospital #askASN Lurking tonight https://t.co/PoHec0gEoO |
 | Nephrology Journal Club @NephJC Would love to see some diabetes docs tonight at 8pm BST to discuss CANVAS trial! #NephJC https://t.co/x4DEAxmTri |
 | Rupe Major @RupeeMaj RT @NephJC: Would love to see some diabetes docs tonight at 8pm BST to discuss CANVAS trial! #NephJC https://t.co/x4DEAxmTri |
| Nephrology Journal Club @NephJC T-10minutes to NephJC! #NephJC |
| Nephrology Journal Club @NephJC Greetings from Dublin! Welcome to NephJC.The topic for tonight:Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. #NephJC |
| Nephrology Journal Club @NephJC Please introduce yourself and disclose any COIs. All lurkers welcome! #NephJC |
| Rupe Major @RupeeMaj Always forget #NephJC |
| Nephrology Journal Club @NephJC Acute on chronic fatigue expected tonight then #nephjc https://t.co/4Qn3vTVO96 |
| Nephrology Journal Club @NephJC @RupeeMaj Welcome Rupe! Yes its definitely not as glossy as EMPA-REG! #nephjc |
| Rupe Major @RupeeMaj #NephJC Rupe Major, renal spr, Leicester. COI: I thought SGLT2 'worked' prior to reading this paper |
| Nephrology Journal Club @NephJC @Errantnephron Welcome Omar! Don't we all! #NephJC |
| Nephrology Journal Club @NephJC @DrMattGB @rasprclub Hi Matt! Sorry to have missed ukkw but the tweeting was stellar! #NephJC |
| Nephrology Journal Club @NephJC Tonight we are discussing the recent @NEJM RCT https://t.co/O9b0Bo1yie #NephJC |
| Nephrology Journal Club @NephJC T0: Who remembers the original SGLT2i trial (EMPA-REG-OUTCOME/Renal) here? #NephJC |
 | Talk_Leicester @talk_leicester RT @DrMattGB: |
| Nephrology Journal Club @NephJC T0:Empagliflozosin reduced the risk of major CVS events and slowed progression of renal disease in T2DM at high risk for CVS events.#nephjc |
| Rupe Major @RupeeMaj @NephJC A recap would be useful #nephjc |
| Nephrology Journal Club @NephJC T0: Does anyone prescribe this now and who for? Any complications encountered? #NephJC |
| Nephrology Journal Club @NephJC @toates_19 Best bloggers/floggers around! #NephJC |
| Rupe Major @RupeeMaj RT @NephJC: T0:Empagliflozosin reduced the risk of major CVS events and slowed progression of renal disease in T2DM at high risk for CVS events.#nephjc |
| Rupe Major @RupeeMaj @NephJC #nephjc |
| Rupe Major @RupeeMaj @toates_19 @NephJC Agree #nephjc |
| Nephrology Journal Club @NephJC T0:I can't honestly say that I have prescribing Empagliflozin but I've nodded approvingly when diabeticrenal patients on them attend #nephjc |
 | Garima Aggarwal @gag_aggarwal @NephJC #nephjc https://t.co/cOqbBcnAw0 |
| Nephrology Journal Club @NephJC RT @caioqualunque: |
| Nephrology Journal Club @NephJC T0: Canagliflozin is not as bioavailable for more SGLT2i specific. CANVAS was designed to assess cardiovascular safety and efficacy #NephJC |
| Nephrology Journal Club @NephJC Thanks Omar! #NephJC https://t.co/zG723JzIen |
| Nephrology Journal Club @NephJC T1: CANVAS (pre FDA approval) + CANVAR-R (Post) = CANVAS program to maximize statistical power. Any issues with this study design? #NephJC |
| Nephrology Journal Club @NephJC Complex and somewhat controversial Study design here #NephJC https://t.co/6sO0AsahVs |
| Nephrology Journal Club @NephJC T1: Essentially only phase 1 of original trial completed combined with another large sister trial #nephjc https://t.co/FOf6DgeIV7 |
| Nephrology Journal Club @NephJC RT @DrMattGB: |
| Nephrology Journal Club @NephJC RT @DrMattGB: |
| Nephrology Journal Club @NephJC T1: Inclusion criteria: T2DM with GFR>30, age>30 with CVS disease or age>50 with 2 or more RFs #NephJC |
| Nephrology Journal Club @NephJC RT @caioqualunque: |
| Nephrology Journal Club @NephJC Explicit hierarchy of outcomes #nephjc https://t.co/IxVZFdlMN4 |
| Nephrology Journal Club @NephJC T1: Note dose differences between CANVAS and CANVAS-R and placebo included standard of care mgmt for glycemia, BP, CVS risk #NephJC |
| Nephrology Journal Club @NephJC T1: Composite primary outcome: death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. #NephJC |
| Rupe Major @RupeeMaj @DrMattGB @NephJC #nephjc took me a while to get head round design, think we'll see more and more RCTs like this in all areas |
| Nephrology Journal Club @NephJC T1: Note funding- The trials were sponsored by Janssen Research and Development and 4 authors were co-employees. #NephJC |
| Nephrology Journal Club @NephJC RT @RupeeMaj: @DrMattGB @NephJC #nephjc took me a while to get head round design, think we'll see more and more RCTs like this in all areas |
| Nephrology Journal Club @NephJC T2: Moving onto results – N=10142 randomised with ITT analysis #NephJC |
| Rupe Major @RupeeMaj @NephJC #nephjc also used a professional med writing service paid for by sponsor |
| Nephrology Journal Club @NephJC @EdoardoMelilli @caioqualunque @toates_19 Hi Edoardo! How stealthy you are! #NephJC |
| Rupe Major @RupeeMaj @NephJC T2: ~70% had normoalbuminuria #nephjc |
| Nephrology Journal Club @NephJC Any major differences in baseline characteristics? #NephJC https://t.co/sKAI1zcynK |
| Nephrology Journal Club @NephJC T2: mean age 63 yrs, 60% men with mean duration of DM 13.5 yrs. #NephJC |
| Nephrology Journal Club @NephJC T2: Mean GFR was 76.5 mL/min, median ACR was 12.3, 22.6% microalbuminuria, 7.6%macroalbuminuria, and 65.6% had a history of CV ds #nephjc |
| Rupe Major @RupeeMaj @NephJC T2: original protocol stated MDRD eGFR, NEJM doesn't state eGFR formula used (as far as I can see) #nephjc |
| Nephrology Journal Club @NephJC @toates_19 Yes maybe more disease in the placebo group which makes the adverse events all the more interesting! #NephJC |
| Nephrology Journal Club @NephJC RT @DrMattGB: |
| Nephrology Journal Club @NephJC T2: Definitely multi-center - 30 countries with 667 sites! #NephJC |
| Rupe Major @RupeeMaj @NephJC @toates_19 Can't see any p values and with that many variables bound to be some 'unbalanced' variables #nephjc |
| Nephrology Journal Club @NephJC Baseline therapy in active vs placebo group #NephJC https://t.co/TStvV9nih0 |
| Nephrology Journal Club @NephJC RT @RupeeMaj: @NephJC @toates_19 Can't see any p values and with that many variables bound to be some 'unbalanced' variables #nephjc |
| Rupe Major @RupeeMaj @caioqualunque #nephjc but even small rise in ACR group predictive of CV risk even in 'normoalbuminuria' group |
| Nephrology Journal Club @NephJC @RupeeMaj @toates_19 Yes would be really useful to see some p values here! #nephjc |
| Rupe Major @RupeeMaj @toates_19 @NephJC #nephjc force of habit to include them! Not necessarily correct |
| Nephrology Journal Club @NephJC T2: Canagliflozin reduced blood sugar, wt and BP #nephjc https://t.co/WYFPZzGSWI |
| Nephrology Journal Club @NephJC T2: Like EMPA-Reg, it did reduce overall mortality but no sig diff in CV mortality #nephjc https://t.co/bnLiUpT5VS |
| Nephrology Journal Club @NephJC RT @caioqualunque: |
| Nephrology Journal Club @NephJC RT @RupeeMaj: @caioqualunque #nephjc but even small rise in ACR group predictive of CV risk even in 'normoalbuminuria' group |
| Nephrology Journal Club @NephJC RT @NephJC: T2: T2: Like EMPA-Reg, it did reduce overall mortality but no sig diff in CV mortality #nephjc https://t.co/bnLiUpT5VS |
| Nephrology Journal Club @NephJC T2: Mean follow up 188.2 weeks –do we need longer to see specific CV mortality benefit in this group? #NephJC |
| Rupe Major @RupeeMaj @DrMattGB @NephJC @toates_19 @kidney_boy #nephjc are you referring to #randomgate ? |
| Nephrology Journal Club @NephJC Yes interesting as there was an interaction with diuretics with added benefit #nephjc https://t.co/Hv2mUXtWXF |
| Nephrology Journal Club @NephJC RT @Errantnephron: |
| Nephrology Journal Club @NephJC T2: details of outcomes following the analytic plan #nephjc https://t.co/GNebV2kIwu |
| Rupe Major @RupeeMaj @toates_19 @NephJC #nephjc my monies on h2o |
| Nephrology Journal Club @NephJC T2: Exploratory renal outcomes - are you persuaded to prescribe? #nephjc https://t.co/a3HOU1kbXO |
| Rupe Major @RupeeMaj @DrMattGB @toates_19 @NephJC #nephjc start with bioimpedence before getting the MRI scanner out |
| Nephrology Journal Club @NephJC Yes good thought! See diuretics slide! #NephJC https://t.co/ZIb4XS6MvQ |
| Nephrology Journal Club @NephJC RT @DrMattGB: |
| Nephrology Journal Club @NephJC T2: Potentially some added benefit when used with diuretics or beta blockers #nephjc https://t.co/isaNAQmKLa |
| Rupe Major @RupeeMaj @toates_19 @NephJC @willkidney #nephjc but no data on individual change in eGFR as was originally promised in protocol |
| Nephrology Journal Club @NephJC T2: what do you think of the renal outcome? Change in ACR with time #nephjc https://t.co/SlDSOIxORq |
| Nephrology Journal Club @NephJC T2: composite renal outcomes #nephjc https://t.co/wVlx1Q2MD3 |
| Rupe Major @RupeeMaj #nephjc T2: have I missed it? No primary outcome by baseline albuminuria status |
 | ab153 @im453 RT @NephJC: T2: T2: Potentially some added benefit when used with diuretics or beta blockers #nephjc https://t.co/isaNAQmKLa |
| ab153 @im453 RT @NephJC: T2: T2: Canagliflozin reduced blood sugar, wt and BP #nephjc https://t.co/WYFPZzGSWI |
| ab153 @im453 RT @NephJC: Yes interesting as there was an interaction with diuretics with added benefit #nephjc https://t.co/Hv2mUXtWXF |
| Nephrology Journal Club @NephJC T2: Here are the adverse events: urogenital infections higher from glycosuria #nephjc https://t.co/cI4eRooIhC |
| Rupe Major @RupeeMaj RT @DrMattGB: |
| Nephrology Journal Club @NephJC T2: Volume depletion was higher, but AKI or hyperkalemia were not significantly different. #NephJC |
| ab153 @im453 RT @Errantnephron: |
| Nephrology Journal Club @NephJC T2: Very surprisingly, more amputations with Canagliflozosin independent of other RFs #nephjc https://t.co/6ik0QXZYOn |
| Rupe Major @RupeeMaj #nephjc T2: serious adverse events overall higher in placebo but each individual adverse event is higher in Canagliflozin group |
| Nephrology Journal Club @NephJC RT @caioqualunque: @NephJC #nephjc very interesting data, but I'd be more interested in knowing how many pts changed CKD A category: |
| Nephrology Journal Club @NephJC RT @EdoardoMelilli: |
| Nephrology Journal Club @NephJC T2: More fractures and renal adverse events #NephJC |
| Rupe Major @RupeeMaj #nephjc ?suggest clustering of adverse events in treatment group |
| Nephrology Journal Club @NephJC T3: Final thoughts on this interesting trial? Will you be prescribing SGLT2i for putative CVS or renal benefits? Or deprescribing?#NephJC |
 | Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 Thank you Paul Conway for representing the #patientvoice with the #device industry This an unmet need cc @knightra @KidneyPatients #nephJC https://t.co/FfJ5OZnhET |
| Nephrology Journal Club @NephJC T3: How do we explain the increased amputations/fractures? #NephJC |
| Rupe Major @RupeeMaj @NephJC #nephjc increased urinary calcium loss?? Not sure |
| Nephrology Journal Club @NephJC RT @RupeeMaj: #nephjc T2: #nephjc T2: serious adverse events overall higher in placebo but each individual adverse event is higher in Canagliflozin group |
| Nephrology Journal Club @NephJC RT @DrMattGB: |
| Rupe Major @RupeeMaj @DrMattGB @NephJC #nephjc https://t.co/xlgXjwceHW |
| Nephrology Journal Club @NephJC RT @RupeeMaj: #nephjc ?suggest clustering of adverse events in treatment group |
| Nephrology Journal Club @NephJC RT @Errantnephron: |
| Nephrology Journal Club @NephJC RT @RupeeMaj: @NephJC #nephjc increased urinary calcium loss?? Not sure |
| Nephrology Journal Club @NephJC RT @DrMattGB: |
| Rupe Major @RupeeMaj RT @DrMattGB: |
| Nephrology Journal Club @NephJC RT @RupeeMaj: @DrMattGB @NephJC #nephjc https://t.co/xlgXjwceHW |
| Nephrology Journal Club @NephJC RT @dguerrot: |
| Rupe Major @RupeeMaj @DrMattGB @NephJC #nephjc increased tubular PO4 resorption |
| Nephrology Journal Club @NephJC Think it might be time to wrap up! Hopefully we haven't contracted some of @toates_19 chronic fatigue! Thanks everyone for coming! #nephjc |
| Rupe Major @RupeeMaj @NephJC @toates_19 #nephjc thanks for informative chat, plenty learnt from a week performed RCT |
| Rupe Major @RupeeMaj @NephJC @toates_19 #nephjc thanks for informative chat, plenty learnt from a well performed RCT |
| Rupe Major @RupeeMaj @caioqualunque @NephJC #nephjc https://t.co/xlgXjwceHW |
| Nephrology Journal Club @NephJC #NephJC has been busy https://t.co/fma9H7opbD |
 | Joel M. Topf, MD FACP @kidney_boy RT @NephJC: #NephJC has been busy https://t.co/fma9H7opbD |
 | محذوف @milardport RT @NephJC: Tonight we are discussing the recent @NEJM RCT https://t.co/O9b0Bo1yie #NephJC |
| محذوف @milardport RT @NephJC: T2: T2: composite renal outcomes #nephjc https://t.co/wVlx1Q2MD3 |
| محذوف @milardport RT @NephJC: Explicit hierarchy of outcomes #nephjc https://t.co/IxVZFdlMN4 |
| محذوف @milardport RT @NephJC: Baseline therapy in active vs placebo group #NephJC https://t.co/TStvV9nih0 |
| محذوف @milardport RT @NephJC: Complex and somewhat controversial Study design here #NephJC https://t.co/6sO0AsahVs |
| محذوف @milardport RT @NephJC: T2: T2: details of outcomes following the analytic plan #nephjc https://t.co/GNebV2kIwu |
| محذوف @milardport RT @NephJC: T2: T2: what do you think of the renal outcome? Change in ACR with time #nephjc https://t.co/SlDSOIxORq |
| محذوف @milardport RT @NephJC: T2: T2: Mean follow up 188.2 weeks –do we need longer to see specific CV mortality benefit in this group? #NephJC |
| محذوف @milardport RT @NephJC: T2: T2: Volume depletion was higher, but AKI or hyperkalemia were not significantly different. #NephJC |
| محذوف @milardport RT @NephJC: T3: T3: How do we explain the increased amputations/fractures? #NephJC |
| محذوف @milardport RT @NephJC: T2: T2: Exploratory renal outcomes - are you persuaded to prescribe? #nephjc https://t.co/a3HOU1kbXO |
| محذوف @milardport RT @NephJC: Any major differences in baseline characteristics? #NephJC https://t.co/sKAI1zcynK |
| محذوف @milardport RT @NephJC: T2: T2: Like EMPA-Reg, it did reduce overall mortality but no sig diff in CV mortality #nephjc https://t.co/bnLiUpT5VS |
| محذوف @milardport RT @NephJC: T2: T2: Potentially some added benefit when used with diuretics or beta blockers #nephjc https://t.co/isaNAQmKLa |
| محذوف @milardport RT @NephJC: T0: T0: Who remembers the original SGLT2i trial (EMPA-REG-OUTCOME/Renal) here? #NephJC |
| محذوف @milardport RT @NephJC: T2: Here are the adverse events: T2: Here are the adverse events: urogenital infections higher from glycosuria #nephjc https://t.co/cI4eRooIhC |
| محذوف @milardport RT @NephJC: T0: T0: Canagliflozin is not as bioavailable for more SGLT2i specific. CANVAS was designed to assess cardiovascular safety and efficacy #NephJC |
| محذوف @milardport RT @NephJC: Greetings from Dublin! Welcome to NephJC.The topic for tonight:Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. #NephJC |
| محذوف @milardport RT @NephJC: T0:I can't honestly say that I have prescribing Empagliflozin but I've nodded approvingly when diabeticrenal patients on them attend #nephjc |
| محذوف @milardport RT @NephJC: T0:Empagliflozosin reduced the risk of major CVS events and slowed progression of renal disease in T2DM at high risk for CVS events.#nephjc |
 | Mana @manasigh RT @Errantnephron: |
#NephJC content from Twitter.